UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Treatment strategies for patients with breast cancer, especially the combination of anthracyclines and HER2-targeted therapies, come with an increased risk of heart failure and cardiac toxicity.

Margetuximab represents an effective new therapeutic option that can be combined safely with a chemotherapy drug of choice for patients with metastatic HER2-positive breast cancer who have undergone multiple lines of prior treatment.

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Hope S. Rugo, MD, FASCO, describes her work in medical oncology, previews the upcoming Miami Breast Cancer Conference, and speaks to what she is looking forward to in 2021 with regard to breast cancer treatment.

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Young Hope Rugo saved up her S&H Green Stamps to buy a children’s chemistry set from a Sears catalog. At the age of 8, Rugo knew she wanted to be a scientist.

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.

Jeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate the need for autologous stem cell transplant in this population.

The combination of tremelimumab and durvalumab improved overall response rate and median overall survival in patients with unresectable hepatocellular carcinoma previously treated with sorafenib.

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Shagun D. Arora, MD, discusses findings from the phase 3 CANDOR, ICARIA-MM, and IKEMA studies which solidified the role of triplet regimens versus doublets in the relapsed/refractory multiple myeloma treatment landscape.

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.